Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05516810
Other study ID # 136133
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 19, 2021
Est. completion date September 30, 2024

Study information

Verified date June 2024
Source King's College Hospital NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational study assessing which ultrasound findings are best at excluding a molar pregnancy in first trimester miscarriage.


Description:

The objectives of this study are to establish the accuracy of ultrasound for the diagnosis of HMs, assess prevalence of these ultrasound features in early pregnancy failure (missed-miscarriages and incomplete miscarriages), and establish which ultrasound signs are the best predictor of HMs on histopathology. The findings of this study will allow us to improve the early diagnosis of HMs by ultrasound therefore allowing us to tailor our counselling and clinical management. All women attending the EPUs and with findings of an early embryonic demise or incomplete miscarriage on transvaginal scan (either by dates or by scan findings) will be eligible to take part in the study. The NICE criteria to diagnose miscarriage will be used. Diagnostic criteria derived from retrospective studies will be used to make the diagnosis of suspected HMs on ultrasound and the presence or absence of these features specifically noted. All participants will be scanned by specialist Gynaecologists who are members of the research team, or the direct clinical care team. Women with suspected HMs on ultrasound will be advised to undergo surgical management of miscarriage, which is in line with current national clinical guidance and maximises the chance of histological diagnosis. All other participants will be offered surgical, medical or expectant management as per standard clinical practice. All women who opt for surgical management, or in whom any pregnancy tissue is available, will have their pregnancy tissue sent for histology, as per national guidance. We will then compare the ultrasound findings with the final histological diagnosis for those women with histopathology specimens and will phone those participants without histopathology specimens to check that their pregnancy tests have reverted to negative 3 weeks after their miscarriage so as to exclude persistent GTN as per standard clinical practice. In addition to this we will perform a blood test for checking pregnancy hormones, beta HCG to assess the correlation between these levels and histologically diagnosed hydatiform moles. All eligible women will be invited to participate in the study and be provided with written consent to have their clinical data included in the study following their ultrasound scan. Participation in the study will be voluntary and refusal to participate will not affect patients' care. Furthermore, taking part in the study will involve an additional blood test, but no other additional interventions over their routine clinical care; however, it will include personal data collection for the purpose of the study. All identifiable data will be anonymised.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 500
Est. completion date September 30, 2024
Est. primary completion date May 5, 2024
Accepts healthy volunteers No
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: - less than 16 weeks gestation by last menstrual period or by ultrasound - singleton pregnancy - ultrasound diagnosis of early embryonic demise or incomplete miscarriage or suspected molar pregnancy. Exclusion Criteria: - Women declining participation and follow up - Women who refuse transvaginal scan - Multiple pregnancy - Ectopic pregnancy - Pregnancy of unknown location - Those unable to understand English to an adequate degree to understand and consent to participation in this study

Study Design


Locations

Country Name City State
United Kingdom King's College Hospital London
United Kingdom University College London Hospital London

Sponsors (2)

Lead Sponsor Collaborator
King's College Hospital NHS Trust University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary histological diagnosis of molar pregnancy yes / no binary outcome measure within a month post miscarriage
Primary hCG undetectable in the urine yes / no Negative pregnancy test post miscarriage for those with no tissue available for histology up to 2 months post miscarriage
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01639976 - Doppler Flow Measurements in Patients With Misoprostol Treatment for Arrested Pregnancy N/A
Recruiting NCT03628625 - Letrozole Pretreatment With Misoprostol fInduction of Abortion In First-Trimester Missed Miscarriage Phase 2
Completed NCT03584698 - Evening Primrose Oil to Misoprostol During Induction of Second-trimester Missed Miscarriage Phase 4
Not yet recruiting NCT04590482 - Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion Phase 4
Recruiting NCT05342467 - Gemeprost Versus Dinoprostone in First Trimester Miscarriages Phase 2
Recruiting NCT03698734 - Evening Primrose Oil Efficacy in Second Trimester Abortion Phase 3
Terminated NCT01615224 - Repeated Doses of Misoprostol for Medical Treatment of Missed Miscarriage Phase 2/Phase 3
Completed NCT05216952 - Ulipristal Acetate for Use in Early Pregnancy Loss Phase 2
Recruiting NCT03081104 - Operative Hysteroscopy and Ultrasound Guided Vacuum Aspiration Versus Blind Vacuum Aspiration for the Treatment of Missed Abortion N/A
Completed NCT00892229 - Buccal Versus Vaginal Misoprostol in Surgical Termination of the First Trimester Missed Abortion in Erbil Phase 2
Active, not recruiting NCT04981457 - Comparative Study Between Combined Vaginal Misoprostol Phase 1
Not yet recruiting NCT06469203 - Oxytocin Effectiveness in First Trimester Dilatation and Curettage - a Double Blind Placebo Controlled Randomized Trial N/A
Recruiting NCT02573051 - Termination Of Anembryonic Pregnancy Phase 2
Not yet recruiting NCT04217265 - Letrozole Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion Phase 4
Not yet recruiting NCT04215835 - Letrozole Pretreatment With Misoprostol Induction of Abortion In First-Trimester Missed Miscarriage Phase 4
Recruiting NCT04705324 - Dilation and Curettage Versus Operative Hysteroscopy for Missed Abortion N/A
Completed NCT02686840 - Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage Phase 3
Terminated NCT02342002 - Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial Phase 4
Recruiting NCT01775917 - The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception. N/A
Active, not recruiting NCT04593108 - Misoprostol With or Without Letrozole in Treatment of Missed Miscarriage